ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.682,40
1,05%
S&P 500
5.363,36
1,81%
US Dollar vs BRL
5,8626
0,00%
Bitcoin
83.162,24
-0,30%
Brent Oil
64,395
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Silence Therapeutics PLC (SLN)

  7. Silence Therapeutics PLC (SLN) Notícias

SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLN
DataHoraFonteTítuloCódigoCompanhia
01/04/202508:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNSilence Therapeutics PLC
31/03/202511:50Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:SLNSilence Therapeutics PLC
27/02/202519:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
27/02/202518:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNSilence Therapeutics PLC
27/02/202509:30Business WireSilence Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:SLNSilence Therapeutics PLC
13/02/202510:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025NASDAQ:SLNSilence Therapeutics PLC
11/02/202520:41Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
02/01/202518:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLNSilence Therapeutics PLC
09/12/202410:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
09/12/202409:30Business WireSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
26/11/202410:00Business WireSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
18/11/202416:30Business WireSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
14/11/202415:13Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/11/202410:00Business WireSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/11/202410:00Business WireSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
27/08/202409:00Business WireSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
15/08/202408:30Business WireSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
27/06/202408:30Business WireSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera PatientsNASDAQ:SLNSilence Therapeutics PLC
24/06/202409:30Business WireSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
20/06/202408:30Business WireSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
30/05/202409:30Business WireSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202409:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202417:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202418:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202409:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202409:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202412:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202408:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202408:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202408:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios